|
A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbopoetin
alfa for Cancer patients with Chemotherapy Associated Anemia. (MCCRC MC04CC):
- Patient must be receiving or scheduled to start chemotherapy
- The patients anemia can not be secondary to
vitamin B12, folic acid deficiency or gastrointestinal bleeding
- Patient must not have uncontrolled hypertension
A Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H For Previously Treated Relapsed or Refractory Patients with Chronic Lympocytic Leukemia. Diagnosis of B-CLL (Chronic Lymphocytic Leukemia (CLL) E2903)
- Patients must require chemotherapy, the last administration of chemotherapy must have been completed less than 6 weeks prior to study treatment.
- Patients must have demonstrated progression after at least one cycle of either alkylating agent based or purine nucleoside based regimen or failed to achieve a meaningful response, or relapsed after prior therapy.
|
